News By Tag
News By Place
Follow on Google News
KRAS inhibitors-Market opportunity, Epidemiology, Forecast,Pipeline and Competitive Analysis, 2020-2
By: Mellalta Meets
While KRAS mutations are present in up to 25% of cancers, the oncogenic variants have different prevalence rates in numerous cancers. As per the American Cancer Society, around 200,000 patients are diagnosed every year with lung adenocarcinomas. That puts the KRAS-G12C population within the USA at 14,000–28,000 patients annually. within the case of KRAS-G12C-positive colorectal cancer (CRC), closer to 3000 patients are diagnosed every year.
Amgen certainly has a head start over its potential opponents, and it is unlikely that a competitor would have the option to sling in front of an expedited development program for AMG 510. Mirati Therapeutics, another competitor, entered the clinic with the KRAS-G12C inhibitor MRTX849, followed by other companies. While there is already a lot of excitement about the new drug, the number of patients who have been treated with it is relatively small.
This KRAS report covers the KRAS market opportunity providing key competitive analysis, 20+ company with pipeline drug profiles, clinical trials, upcoming events, other Developments (Collaborations Details, Funding, etc.), Epidemiology forecast of Cancers with KRAS mutation and % of mutation frequency, licensing and deals, as well as presenting market forecast from 2019 to 2030.
Key Takeaways from the Report
• Indication Prioritization:
• KRAS Mutated Cancers Epidemiology Forecast from 2019-2030
• Business Transactions & Strategies: Key collaborations and deal values
• Pipeline Development:
• Market Forecast of KRAS Inhibitors from 2019-2030
• Recent & Upcoming events
Submit your Request for Proposals at email@example.com